Single-receptor and dual-receptor research compounds reach one or two incretin pathways. Retatrutide reaches three, GLP-1, GIP and glucagon, from a single sequence, and that combined activity is the reason it appears so often in receptor-pharmacology work.
The molecule occupies the GLP-1, GIP and glucagon receptors, three pathways with distinct endogenous ligands, from a single sequence. The published question is what those signals do when they arrive together instead of one at a time. This 40mg vial carries double the content for longer research runs.
Commonly studied alongside a growth-hormone peptide in body-composition research, where lean tissue is tracked as its own endpoint.
